These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 27931345

  • 1. Factors associated with sputum culture conversion in multidrug-resistant pulmonary tuberculosis.
    Velayutham B, Nair D, Kannan T, Padmapriyadarsini C, Sachdeva KS, Bency J, Klinton JS, Haldar S, Khanna A, Jayasankar S, Swaminathan S.
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):1671-1676. PubMed ID: 27931345
    [Abstract] [Full Text] [Related]

  • 2. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
    Parmar MM, Sachdeva KS, Dewan PK, Rade K, Nair SA, Pant R, Khaparde SD.
    PLoS One; 2018 Dec; 13(4):e0193903. PubMed ID: 29641576
    [Abstract] [Full Text] [Related]

  • 3. Body mass index predictive of sputum culture conversion among MDR-TB patients in Indonesia.
    Putri FA, Burhan E, Nawas A, Soepandi PZ, Sutoyo DK, Agustin H, Isbaniah F, Dowdy DW.
    Int J Tuberc Lung Dis; 2014 May; 18(5):564-70. PubMed ID: 24903794
    [Abstract] [Full Text] [Related]

  • 4. Time to sputum smear and culture conversions in multidrug resistant tuberculosis at University of Gondar Hospital, Northwest Ethiopia.
    Shibabaw A, Gelaw B, Wang SH, Tessema B.
    PLoS One; 2018 May; 13(6):e0198080. PubMed ID: 29944658
    [Abstract] [Full Text] [Related]

  • 5. Implementation of the INNO-LiPA Rif. TB® line-probe assay in rapid detection of multidrug-resistant tuberculosis in Latvia.
    Skenders GK, Holtz TH, Riekstina V, Leimane V.
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1546-52, i. PubMed ID: 22008771
    [Abstract] [Full Text] [Related]

  • 6. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome.
    Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E, Skripconoka V, Wells CD, Leimane V.
    Ann Intern Med; 2006 May 02; 144(9):650-9. PubMed ID: 16670134
    [Abstract] [Full Text] [Related]

  • 7. Genetic mutations associated with rifampicin and isoniazid resistance in MDR-TB patients in North-West India.
    Kumar P, Kumar P, Balooni V, Singh S.
    Int J Tuberc Lung Dis; 2015 Apr 02; 19(4):434-9. PubMed ID: 25859999
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of genotype MTBDRplus VER 2.0 line probe assay for the detection of MDR-TB in smear positive and negative sputum samples.
    Meaza A, Kebede A, Yaregal Z, Dagne Z, Moga S, Yenew B, Diriba G, Molalign H, Tadesse M, Adisse D, Getahun M, Desta K.
    BMC Infect Dis; 2017 Apr 17; 17(1):280. PubMed ID: 28415989
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of Xpert(®) MTB/RIF assay: diagnosis and treatment outcomes in rifampicin-resistant tuberculosis.
    Kim YW, Seong MW, Kim TS, Yoo CG, Kim YW, Han SK, Yim JJ.
    Int J Tuberc Lung Dis; 2015 Oct 17; 19(10):1216-21. PubMed ID: 26459536
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the validity of smear and culture conversion as a prognostic marker of treatment outcome in patients with multidrug-resistant tuberculosis.
    Alene KA, Viney K, Yi H, McBryde ES, Yang K, Bai L, Gray DJ, Xu Z, Clements ACA.
    PLoS One; 2018 Oct 17; 13(5):e0197880. PubMed ID: 29791488
    [Abstract] [Full Text] [Related]

  • 11. Factors affecting time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis in China.
    Liu Q, Lu P, Martinez L, Yang H, Lu W, Ding X, Zhu L.
    BMC Infect Dis; 2018 Mar 06; 18(1):114. PubMed ID: 29510666
    [Abstract] [Full Text] [Related]

  • 12. Diabetes mellitus, smoking status, and rate of sputum culture conversion in patients with multidrug-resistant tuberculosis: a cohort study from the country of Georgia.
    Magee MJ, Kempker RR, Kipiani M, Tukvadze N, Howards PP, Narayan KM, Blumberg HM.
    PLoS One; 2014 Mar 06; 9(4):e94890. PubMed ID: 24736471
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Factors associated with time to sputum culture conversion of rifampicin-resistant tuberculosis patients in Klaipeda, Lithuania in 2016-2019: a cohort study.
    Diktanas S, Korotych O, Sereda Y, Gozalov O, Rubcova O, Achar J.
    Monaldi Arch Chest Dis; 2021 Jan 14; 91(1):. PubMed ID: 33470085
    [Abstract] [Full Text] [Related]

  • 18. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M, Mok J, Kim DK, Shim TS, Koh WJ, Jeon D, Lee T, Lee SH, Kim JS, Park JS, Lee JY, Kim SY, Lee JH, Jo KW, Jhun BW, Kang YA, Ahn JH, Kim CK, Shin S, Song T, Shin SJ, Kim YR, Ahn H, Hahn S, Won HJ, Jang JY, Cho SN, Yim JJ.
    Trials; 2019 Jan 16; 20(1):57. PubMed ID: 30651149
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Determinants of sputum culture conversion time in multidrug-resistant tuberculosis patients in ALERT comprehensive specialized hospital, Addis Ababa, Ethiopia: A retrospective cohort study.
    Abebe M, Atnafu A, Tilahun M, Sero N, Neway S, Alemu M, Tesfaye G, Mihret A, Bobosha K, Wan C.
    PLoS One; 2024 Jan 16; 19(5):e0304507. PubMed ID: 38820260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.